Flying Eze and its trusted partners need your
permission to store and access cookies, unique identifiers, personal data, and information on your
browsing behaviour on this device. This only applies to Flying Eze. You don’t have to accept, and
you
can change your preferences at any time via the Privacy Options link at the bottom of this screen. If
you don’t accept, you may will still see some personalised ads and content.
Cookies, device identifiers, or other information can be stored or accessed on
your device for the purposes presented to you.
Ads and content can be personalised based on a profile. More data can be added
to better personalise ads and content. Ad and content performance can be
measured. Insights about audiences who saw the ads and content can be derived.
Data can be used to build or improve user experience, systems and software.
Precise geolocation and information about device characteristics can be used.
If you don’t want to accept, please select Read More option below where you can also see how and
why your data may be used. You can also see where we or our partners claim a legitimate interest and
object to the processing of your data.
Between November and February, nearly 600 departing passengers at YVR took a COVID-19 rapid antigen test and all came back negative. Researchers said the results led them to conclude that transmissible infection in airline passengers departing from YVR is likely to be less than one per cent.
Under the pilot project guidelines, WestJet travellers were given the chance to opt-in and take a rapid test before flying.
If they tested positive, they were not permitted to fly that day, pending a lab-confirmed PCR test of their results, and would be rebooked on a future flight at no cost.
Researchers said the rapid tests took between 15 to 20 minutes to complete and led to minimal disruptions.
“Rapid antigen testing is a critically important tool – and perhaps an underutilized tool – in our ability to prevent and control COVID-19,” co-principal investigator Dr. Marc Romney said in a statement.
“The findings from our study provide further evidence that this technology can be successfully deployed in an airport setting, and that rapid antigen testing performs surprisingly well – even in a low- prevalence population such as air travellers.”
Vancouver Airport Authority president and CEO Tamara Vrooman said they hope the results will help the travel industry reopen safely and prove useful for other industries.